Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

TNFα facilitates clonal expansion of JAK2 V617F positive cells in myeloproliferative neoplasms

Angela G. Fleischman, Karl J. Aichberger, Samuel B. Luty, Thomas G. Bumm, Curtis L. Petersen, Shirin Doratotaj, Kavin B. Vasudevan, Dorian H. LaTocha, Fei Yang, Richard D. Press, Marc M. Loriaux, Heike L. Pahl, Richard T. Silver, Anupriya Agarwal, Thomas O'Hare, Brian J. Druker, Grover C. Bagby, Michael W. Deininger

Blood (2011) 118 (24): 6392–6398.

https://doi.org/10.1182/blood-2011-04-348144

Published: 2011

Includes: Supplemental data

Journal Articles

Nilotinib Exerts Direct Effects on Vascular Endothelial Cells and May Act As a Co-Trigger of Atherosclerosis in Patients with Ph+ CML

Emir Hadzijusufovic, DVM, Susanne Herndlhofer, Karl J. Aichberger, MD, PhD, Viviane Ghanim, M.D., Verena Suppan, BSc, Sabine Cerny-Reiterer, D.V.M., Wolfgang R Sperr, MD, Peter Valent, M.D.

Blood (2011) 118 (21): 2753.

https://doi.org/10.1182/blood.V118.21.2753.2753

Published: 2011

Journal Articles

Identification of Basophils as Source of Hepatocyte Growth Factor (HGF) In CML: a Potential Trigger of Disease Acceleration.

Sabine Cerny-Reiterer, DVM, Karl J. Aichberger, MD, Harald Herrmann, MD, Gregor Hoermann, MD, Barbara Peter, MVM, Leonhard Muellauer, MD, Matthias Mayerhofer, MD, Peter Valent, MD

Blood (2010) 116 (21): 1202.

https://doi.org/10.1182/blood.V116.21.1202.1202

Published: 2010

Journal Articles

Jak2 V617F Induced TNF Resistance as a Mechanism of Clonal Expansion In Myeloproliferative Neoplasm

Angela G. Fleischman, MD, PhD, Karl J. Aichberger, MD, PhD, Curtis L Petersen, Shirin Doratotaj, MD, Thomas G Bumm, MD, Heike L. Pahl, PhD, Brian J Druker, MD, Michael W Deininger, MD, PhD

Blood (2010) 116 (21): 795.

https://doi.org/10.1182/blood.V116.21.795.795

Published: 2010

Journal Articles

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

Jeffrey W. Tyner, Thomas G. Bumm, Jutta Deininger, Lisa Wood, Karl J. Aichberger, Marc M. Loriaux, Brian J. Druker, Christopher J. Burns, Emmanuelle Fantino, Michael W. Deininger

Blood (2010) 115 (25): 5232–5240.

https://doi.org/10.1182/blood-2009-05-223727

Published: 2010

Includes: Supplemental data

Journal Articles

Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs

Karl J. Aichberger, Karoline V. Gleixner, Irina Mirkina, Sabine Cerny-Reiterer, Barbara Peter, Veronika Ferenc, Michael Kneidinger, Christian Baumgartner, Matthias Mayerhofer, Alexander Gruze, Winfried F. Pickl, Christian Sillaber, Peter Valent

Blood (2009) 114 (26): 5342–5351.

https://doi.org/10.1182/blood-2008-08-175190

Published: 2009

Journal Articles

Tumor Necrosis Factor-Alpha (TNF) Expression Is Elevated in Myelo-Proliferative Neoplasms (MPN) and Modulated by Inhibition of JAK2 V617F.

Karl J. Aichberger, MD, PhD, Angela G. Fleischman, MD, PhD, Shirin Doratotaj, MD, Thomas G.P. Bumm, MD, Richard T. Silver, MD, Thomas G. Deloughery, MD, Heike L. Pahl, PhD, Brian J. Druker, MD, Christopher J. Burns, Michael Deininger, MD, PhD

Blood (2009) 114 (22): 2917.

https://doi.org/10.1182/blood.V114.22.2917.2917

Published: 2009

Journal Articles

Same mutation, different allele

Karl J. Aichberger, Angela G. Fleischman, Michael W. Deininger

Blood (2009) 114 (14): 2853–2854.

https://doi.org/10.1182/blood-2009-07-229906

Published: 2009

Journal Articles

Effects of the Mcl-1/Bcl-2 Inhibitor GX015-070 (Obatoclax ® ) on Growth and Viability of Canine and Human Neoplastic Mast Cells

Barbara Peter, MVM, Karl J. Aichberger, MD, Karoline V. Gleixner, MD, Veronika Ferenc, MD, Alexander Gruze, Winfried F. Pickl, MD, Michael Willmann, DVM, Peter Valent, MD

Blood (2008) 112 (11): 861.

https://doi.org/10.1182/blood.V112.11.861.861

Published: 2008

Journal Articles

Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib

Matthias Mayerhofer, Karoline V. Gleixner, Julia Mayerhofer, Gregor Hoermann, Eva Jaeger, Karl J. Aichberger, Rene G. Ott, Khaled Greish, Hideaki Nakamura, Sophia Derdak, Puchit Samorapoompichit, Winfried F. Pickl, Veronika Sexl, Harald Esterbauer, Ilse Schwarzinger, Christian Sillaber, Hiroshi Maeda, Peter Valent

Blood (2008) 111 (4): 2200–2210.

https://doi.org/10.1182/blood-2006-11-055723

Published: 2008

Journal Articles

Liposomal Cytarabine (DepoCyte) for Treatment of Myeloid CNS Relapse in CML Occurring during Therapy with Imatinib.

Karl J. Aichberger, MD, MSci, Susanne Herndlhofer, Hermine Agis, MD, Wolfgang R. Sperr, MD, Werner Rabitsch, MD, Harald Esterbauer, MD, PhD, Paul Knoebl, MD, Christian Sillaber, MD, Ulrich Jaeger, MD, Peter Valent, MD

Blood (2007) 110 (11): 4556.

https://doi.org/10.1182/blood.V110.11.4556.4556

Published: 2007

Journal Articles

Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells

Rudin Kondo, Karoline V. Gleixner, Matthias Mayerhofer, Anja Vales, Alexander Gruze, Puchit Samorapoompichit, Khaled Greish, Maria-Theresa Krauth, Karl J. Aichberger, Winfried F. Pickl, Harald Esterbauer, Christian Sillaber, Hiroshi Maeda, Peter Valent

Blood (2007) 110 (2): 661–669.

https://doi.org/10.1182/blood-2006-10-054411

Published: 2007

Includes: Supplemental data

Journal Articles

Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412

Karl J. Aichberger, Matthias Mayerhofer, Karoline V. Gleixner, Maria-Theresa Krauth, Alexander Gruze, Winfried F. Pickl, Volker Wacheck, Edgar Selzer, Leonhard Müllauer, Hermine Agis, Christian Sillaber, Peter Valent

Blood (2006) 109 (7): 3031–3041.

https://doi.org/10.1182/blood-2006-07-032714

Published: 2006

Journal Articles

Synergistic Growth-Inhibitory Effects of Two Tyrosine Kinase Inhibitors, Dasatinib and PKC412, on Neoplastic Mast Cells Expressing the D816V-Mutated Oncogenic Variant of KIT.

Karoline V. Gleixner, MD, Matthias Mayerhofer, MD, Karoline Sonneck, MD, Alexander Gruze, Puchit Samorapoompichit, MD, Karl J. Aichberger, MD, Francis Y. Lee, PhD, Paul W. Manley, PhD, Doriano Fabbro, PhD, Winfried F. Pickl, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2006) 108 (11): 526.

https://doi.org/10.1182/blood.V108.11.526.526

Published: 2006

Journal Articles

The KIT D816V-Targeting Drug PKC412 Induces Re-Expression of Bim and Synergizes with Mcl-1 Antisense Oligonucleotides in Producing Growth Inhibition in Neoplastic Human Mast Cells.

Karl J. Aichberger, MD, PhD, Matthias Mayerhofer, MD, Karoline V. Gleixner, MD, Maria-Theresa Krauth, MD, Alexander Gruze, Winfried F. Pickl, MD, Volker Wacheck, MD, Edgar Selzer, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2006) 108 (11): 1437.

https://doi.org/10.1182/blood.V108.11.1437.1437

Published: 2006

Journal Articles

The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells

Karl J. Aichberger, Matthias Mayerhofer, Anja Vales, Maria-Theresa Krauth, Karoline V. Gleixner, Martin Bilban, Harald Esterbauer, Karoline Sonneck, Stefan Florian, Sophia Derdak, Winfried F. Pickl, Hermine Agis, Andras Falus, Christian Sillaber, Peter Valent

Blood (2006) 108 (10): 3538–3547.

https://doi.org/10.1182/blood-2005-12-028456

Published: 2006

Journal Articles

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects

Karoline V. Gleixner, Matthias Mayerhofer, Karl J. Aichberger, Sophia Derdak, Karoline Sonneck, Alexandra Böhm, Alexander Gruze, Puchit Samorapoompichit, Paul W. Manley, Doriano Fabbro, Winfried F. Pickl, Christian Sillaber, Peter Valent

Blood (2006) 107 (2): 752–759.

https://doi.org/10.1182/blood-2005-07-3022

Published: 2006

Journal Articles

PKC412 Inhibits In Vitro Growth of Neoplastic Mast Cells Expressing the D816V-Mutated Variant of KIT: Comparison with AMN107 and Imatinib, and Evaluation of Drug-Interactions.

Karoline V. Gleixner, MD, Matthias Mayerhofer, MD, Karl J. Aichberger, MD, Sophia Derdak, PhD, Karoline Sonneck, MD, Alexandra Boehm, MD, Puchit Samorapoompichit, MD, Alexander Gruze, Winfried Pickl, Paul Manley, Doriano Fabbro, Christian Sillaber, Peter Valent

Blood (2005) 106 (11): 3523.

https://doi.org/10.1182/blood.V106.11.3523.3523

Published: 2005

Journal Articles

Identification of Mcl-1 as a Novel Target in Neoplastic Mast Cells and Demonstration of Cooperative Growth-Inhibitory Effects of mcl-1 Antisense Oligonucleotides, PKC412, and AMN107.

Karl J. Aichberger, MD, PhD, Matthias Mayerhofer, MD, Karoline V. Gleixner, Maria-Theresa Krauth, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Volker Wacheck, MD, Edgar Selzer, MD, Hermine Agis, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2005) 106 (11): 3516.

https://doi.org/10.1182/blood.V106.11.3516.3516

Published: 2005

Journal Articles

Inhibition of Growth of Neoplastic Mast Cells by CD44 mAb A3D8 Is Associated with G1 Cell Cycle Arrest and Apoptosis.

Alexandra Boehm, MD, Stefan Florian, MD, Karoline Gleixner, Karoline Sonneck, MD, Karl J. Aichberger, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Peter Valent, MD, Wolfgang R. Sperr, MD

Blood (2005) 106 (11): 3518.

https://doi.org/10.1182/blood.V106.11.3518.3518

Published: 2005

NARROW

TNFα facilitates clonal expansion of JAK2 V617F positive cells in myeloproliferative neoplasms

Nilotinib Exerts Direct Effects on Vascular Endothelial Cells and May Act As a Co-Trigger of Atherosclerosis in Patients with Ph+ CML

Identification of Basophils as Source of Hepatocyte Growth Factor (HGF) In CML: a Potential Trigger of Disease Acceleration.

Jak2 V617F Induced TNF Resistance as a Mechanism of Clonal Expansion In Myeloproliferative Neoplasm

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs

Tumor Necrosis Factor-Alpha (TNF) Expression Is Elevated in Myelo-Proliferative Neoplasms (MPN) and Modulated by Inhibition of JAK2 V617F.

Same mutation, different allele

Effects of the Mcl-1/Bcl-2 Inhibitor GX015-070 (Obatoclax ® ) on Growth and Viability of Canine and Human Neoplastic Mast Cells

Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib

Liposomal Cytarabine (DepoCyte) for Treatment of Myeloid CNS Relapse in CML Occurring during Therapy with Imatinib.

Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells

Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412

Synergistic Growth-Inhibitory Effects of Two Tyrosine Kinase Inhibitors, Dasatinib and PKC412, on Neoplastic Mast Cells Expressing the D816V-Mutated Oncogenic Variant of KIT.

The KIT D816V-Targeting Drug PKC412 Induces Re-Expression of Bim and Synergizes with Mcl-1 Antisense Oligonucleotides in Producing Growth Inhibition in Neoplastic Human Mast Cells.

The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects

PKC412 Inhibits In Vitro Growth of Neoplastic Mast Cells Expressing the D816V-Mutated Variant of KIT: Comparison with AMN107 and Imatinib, and Evaluation of Drug-Interactions.

Identification of Mcl-1 as a Novel Target in Neoplastic Mast Cells and Demonstration of Cooperative Growth-Inhibitory Effects of mcl-1 Antisense Oligonucleotides, PKC412, and AMN107.

Inhibition of Growth of Neoplastic Mast Cells by CD44 mAb A3D8 Is Associated with G1 Cell Cycle Arrest and Apoptosis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only